Enterovirus infection in Korean children and anti-enteroviral potential candidate agents

Kwi Sung Park, PhD¹, Young Jin Choi, MD, PhD², Joon Soo Park, MD, PhD³

¹Chungcheongnam-do Institute of Health and Environmental Research, Daejeon, Departments of Laboratory Medicine and ²Pediatrics, Soonchunhyang University Cheonan Hospital, Soonchunhyang University College of Medicine, Cheonan, Korea

Received: 9 May 2012, Accepted: 25 August 2012
Corresponding author: Joon Soo Park, MD, PhD
Department of Pediatrics, Soonchunhyang University Cheonan Hospital, Soonchunhyang University College of Medicine, 31 Suncheonhyang-ro, Dongnam-gu, Cheonan 330-930, Korea
Tel: +82-41-570-2163, Fax: +82-41-572-4996, E-mail: pjstable@schmc.ac.kr

Copyright © 2012 by The Korean Pediatric Society

Introduction

The clinical manifestations of human enterovirus (HEV) infections vary, ranging from asymptomatic, mild respiratory illness, and aseptic meningitis to serious symptoms such as myocarditis, encephalitis, acute flaccid paralysis, and severe neonatal sepsis-like disease[1-3].

Fatal enterovirus (EV)71 infections are frequently reported[4-6]. EV71-infected children can develop severe neurological complications, which can lead to rapid clinical deterioration and even death[7,8]. Additionally, some reports have suggested that enteroviral diseases may be expanded to other serious human ailments such as autoimmunity, type 1 diabetes[9], Sjögren’s syndrome[10], various neurological disorders[11], and some tumors[12].

Although most enterovirus infections are not serious enough to be life threatening, several enteroviruses such as enterovirus 71 are responsible for severe, potentially life-threatening disease. The epidemic patterns of enteroviruses occur regularly during the year, but they may change due to environmental shifts induced by climate change due to global warming. Therefore, enterovirus epidemiological studies should be performed continuously as a basis for anti-viral studies. A great number of synthesized antiviral compounds that work against enteroviruses have been developed but only a few have demonstrated effectiveness in vivo. No proven effective antiviral agents are available for enterovirus disease therapy. The development of a new antiviral drug is a difficult task due to poor selective toxicity and cost. To overcome these limitations, one approach is to accelerate the availability of other existing antiviral drugs approved for antiviral effect against enteroviruses, and the other way is to screen traditional medicinal plants.

Key words: Enterovirus, Antiviral agents, Medicinal plants

The risks of emerging diseases associated with HEV infections have increased; however, there are no proven specific therapeutic antiviral agents or vaccines that can prevent HEV diseases. The only mainstay of treatment is supportive care to control fever and pain, thus, new and more effective antiviral agents for HEV infection are needed.

We describe HEV infections, including epidemiology in Korean children, and introduce current antiviral agent studies, although no proven antiviral drugs are available to date.

HEVs

1. Classification

The HEV genus belongs to the Picornaviridae family. HEVs were originally divided into five subgroups, including polioviruses,
group A coxsackieviruses (CVA), group B coxsackieviruses (CVB), echoviruses (ECV), and “newer” EVs. This genus, with the exception of polioviruses, comprises over 90 immunologically distinct serotypes that cause human infections. These viruses are also classified genetically into HEV-A to HEV-D, and shown in Table 1.\(^\text{13-16}\)

2. \textbf{Pathogenesis}

EV infections are acquired by ingestion or respiratory droplet that is shed in the feces or upper respiratory tract. Initial viral replication occurs in the mucosal tissues of the intestine and nasopharynx. Initial replication in the pharynx and intestine is followed within days by multiplication in lymphoid tissues such as the tonsils, Peyer’s patches, and regional lymph nodes. A transient viremia (minor viremia) results in a spread to distant parts of the reticuloendothelial system, including the liver, spleen, bone marrow, and distant lymph nodes.

Further replication in these organs leads to a sustained “major” viremia with dissemination of the virus to target organs such as the central nervous system, heart, and skin, resulting in a clinical infection. Tropism to target organs is determined, in part, by the infecting serotype.\(^\text{16,17}\)

3. \textbf{Clinical manifestations}

Although most infections in children subside mildly or asymptomatically, HEVs can also be responsible for severe, potentially life-threatening disease.\(^\text{18}\)

HEVs can cause asymptomatic infections, nonspecific febrile illness, hand-foot-and-mouth disease, herpangina, and acute hemorrhagic conjunctivitis. HEVs can also cause respiratory diseases such as an exacerbation of asthma, apnea, respiratory distress, pneumonia, otitis media, bronchiolitis, croup, parotitis, pharyngotonsillitis, and pleuropneumonia. HEVs are involved in myocarditis and pericarditis as well as gastrointestinal diseases, such as emesis, abdominal pain, diarrhea, hematochezia, pneumatosis intestinalis, necrotizing enterocolitis, hepatitis, and pancreatitis. HEVs cause genitourinary diseases, such as orchitis, epididymitis, nephritis, and immunoglobulin A nephropathy and neurological manifestations including aseptic meningitis, encephalitis, polioencephalitis-like acute flaccid paralysis, brainstem encephalitis, Guillain-Barré syndrome, transverse myelitis, cerebellar ataxia, opsoclonus-myoclonus syndrome, as well as benign intracranial hypertension. HEVs are involved in cutaneous manifestations such as, exanthem, petechial rashes, purpuric rashes and papular acrodermatitis. HEVs have been associated with myositis, arthritis and neonatal infections.

HEV infections may initiate an inflammatory insult to pancreatic islet cells and thereby contribute to the development of type 1 insulin-dependent diabetes mellitus.\(^\text{16,19}\)

4. \textbf{Epidemiology of HEV infection}

HEV infections are common in children particularly those <1 year of age.\(^\text{20,21}\) Various HEV serotypes are spreading globally by temporal and regional distribution. Epidemics of HEV typically peak during the summer and fall, and predominant serotypes are often associated with a single outbreak.\(^\text{22}\) The predominant serotypes vary from year to year, and HEV epidemics in Korea may be affected by environmental shifts induced by climate change due to global warming.\(^\text{21,23}\) Therefore, systemic long-term epidemiological studies should be conducted to prevent the spread of HEVs and to identify proper anti-viral therapies.

HEVs are the leading cause of aseptic meningitis, which is the most frequent central nervous system infection worldwide.\(^\text{24,25}\) The isolation of HEVs often focuses on a single outbreak with aseptic meningitis. Aseptic meningitis in Korea was the most common manifestation in children with enteroviral infection,\(^\text{22}\) the Chungnam data that is shown in Table 2 show similar results. Followed by aseptic meningitis, HEVs are isolated from patients with respiratory illness, acute gastroenteritis, herpangina, and hand foot mouth disease (HFMD) (Table 2).\(^\text{21,28}\) No disease is uniquely associated with any specific serotype, although certain manifestations are preferentially associated with specific serotypes.\(^\text{26}\)

HEVs infect millions of people worldwide each year, mostly

| Table 1. Correspondence between Human Enterovirus Species and Serotypes |
|-----------------------------|-----------------------------|-----------------------------|-----------------------------|
| **Species** | **Poliovirus** | **Coxackievirus A** | **Coxackievirus B** | **Echovirus** | **Enterovirus** |
| HEV-A | - | CVA2–8, 10, 12, 14, 16 | - | - | EV71, 76, 89–92 |
| HEV-B | - | CVA9 | CVB1-6 | ECV1–9, 11–21, 24–27, 29–33 | EV69, 73–75, 77–88, 93, 95, 97, 98, 100, 101, 107 |
| HEV-C | PV1–3 | CVA1, 11, 13, 15, 17–22, 24 | - | - | EV96, 104, 105, 109, 116 |
| HEV-D | - | - | - | - | EV68, 70, 94 |

\(^{16}\) Data from National Center for Biotechnology Information.\(^{16}\)

HEV, human enterovirus; CVA, coxsackievirus A; CVB, coxsackievirus B; ECV, echovirus; EV, enterovirus.
children and young adults, and different HEV serotypes are spreading globally each year. The prevalent HEV serotypes vary yearly among ECV6, 9, 18, and 30, but CVB1 is the type most frequently isolated in Europe and the USA in recent years. Since 1993, when nationwide surveillance began in Korea, there have been reports of summer outbreaks of various HEV types, such as ECV6, 9, 30, and CVA24. The recent epidemic of HEV serotypes in Chungnam, Korea included EV71, ECV5, 6, 18, 30, and CVB1 and 5 (Table 3) and reflected the national trend. In a previous study, EV71 was detected in 5 cases among a total 24 enterovirus cases (20%) in 2007 and 12 cases (11%) among 107 cases in 2009. There were no identified cases of EV 71 in 2005, 2006 and 2008 (Table 3). Severe EV 71-induced HFMD with neurological complications was frequently reported in Korea nowadays.

In individuals <1 year of age, the number of tested samples and HEV-positive cases were high in Chungnam, Korea (Table 4). Typically, HEV-positive cases are widely distributed throughout the year in tropical and semitropical regions, prominent in the summer and fall, but are far less detected in the winter and spring. The temporal pattern of HEV epidemics in Chungnam, Korea represents a remarkable seasonality, with cases occurring from June to August. The ratio of male to female HEV-positive patients was approximately 1.6:1 in the Chungnam area.

Generally, serotypes of HEVs epidemic were different each year, and epidemic patterns may change due to environmental changes. HEVs have a high mutation rate due to the absence of proofreading activity during genome replication. Additionally, about a 20% genetic difference occurred between prototype strains and the current widespread strains, and the difference was at the HEV cleavage site. Thus, the development and screening of antiviral drugs against HEV should focus on the current epidemic strains.

**Antiviral agents against HEVs**

No HEV-specific antiviral drugs have been available for clinical use until recently. A great number of synthesized antiviral compounds against HEVs in vitro have been described but only a few of them have shown effectiveness in vivo, and none have been approved for clinical use.

| Table 2. Distribution of Clinical Symptoms for Enterovirus-Positive Cases in Chungnam, Korea |
|---------------------------------------------|
| Diagnosis | Enteroviruses, n (%) | Total |
| 2005 | 2006 | 2007 | 2008 | 2009 |
| Aseptic meningitis | 57 (72) | 27 (73.0) | 15 (63) | 66 (81) | 60 (56) | 225 (69) |
| Respiratory illness | 13 (17) | 4 (11) | 2 (8.3) | 5 (6) | 16 (15) | 40 (12) |
| Acute gastroenteritis | 5 (6) | 4 (11) | 3 (13) | 4 (5) | 14 (13) | 30 (9) |
| Herpangina | 1 (1) | 0 (0) | 0 (0) | 1 (1) | 8 (7) | 10 (3) |
| Hand, foot, and mouth disease | 0 (0) | 0 (0) | 2 (8) | 1 (1) | 1 (1) | 4 (1) |
| Others | 3 (4) | 2 (5) | 2 (8) | 5 (6) | 8 (8) | 20 (6) |
| Total | 79 (100) | 37 (100) | 24 (100) | 82 (100) | 107 (100) | 329 (100) |

| Table 3. The Number of Enteroviruses Isolated in Chungnam, Korea from 2005 to 2009 |
|---------------------------------------------|
| Type of enterovirus | Enteroviruses | Total |
| 2005 | 2006 | 2007 | 2008 | 2009 | Proportion |
| Coxsackievirus A2 | 11 | 11 | 3.3 |
| Coxsackievirus A4 | 1 | 2 | 4 | 7 | 2.1 |
| Coxsackievirus A5 | 3 | 3 | 0.9 |
| Coxsackievirus A6 | 1 | 2 | 3 | 0.9 |
| Coxsackievirus A8 | 2 | 2 | 0.6 |
| Coxsackievirus A9 | 1 | 2 | 3 | 0.9 |
| Coxsackievirus A10 | 1 | 1 | 1 | 0.3 |
| Coxsackievirus A13 | 1 | 1 | 0.3 |
| Coxsackievirus A16 | 1 | 1 | 8 | 10 | 3.0 |
| Coxsackievirus A1 | 1 | 1 | 3 | 34 | 11.9 |
| Coxsackievirus A2 | 3 | 3 | 0.9 |
| Coxsackievirus B3 | 1 | 2 | 2 | 5 | 1.5 |
| Coxsackievirus B4 | 2 | 2 | 0.6 |
| Coxsackievirus B5 | 21 | 21 | 42 | 12.8 |
| Echovirus 5 | 14 | 14 | 4.3 |
| Echovirus 6 | 1 | 19 | 20 | 6.1 |
| Echovirus 7 | 3 | 3 | 0.9 |
| Echovirus 9 | 7 | 3 | 2 | 12 | 3.7 |
| Echovirus 11 | 1 | 2 | 3 | 0.9 |
| Echovirus 16 | 1 | 1 | 0.3 |
| Echovirus 18 | 38 | 38 | 11.6 |
| Echovirus 25 | 7 | 7 | 2.1 |
| Echovirus 30 | 1 | 42 | 43 | 13.1 |
| Enterovirus 71 | 5 | 12 | 17 | 5.2 |
| Untypable | 10 | 5 | 6 | 12 | 39 | 11.9 |
| Total | 79 | 37 | 24 | 82 | 107 | 329 | 100.0 |

Modified from Baek et al. J Microbiol Biotechnol 2009;19:1055-64, with permission of Korean Society for Microbiology and Biotechnology and reproduced from Baek et al. Virol J 2011;8:297.
1. Current antiviral drugs

The current antiviral drug armamentarium comprises approximately 40 compounds that have been formally licensed for chemotherapy in humans with viral infection. Most are used to treat infections caused by human immunodeficiency virus, hepatitis B virus, herpesviruses, varicella-zoster virus, cytomegalovirus, influenza virus (IFN), respiratory syncytial virus, and hepatitis C virus. At present, there is no specific antiviral drug to treat or prevent diseases caused by HEVs.

1) WIN series

The commonly known “WIN” compounds developed by Sterling-Winthrop represent the first demonstration of oral efficacy of an anti-HEV agent. These compounds moderately prevent virion uncoating activity against HEVs both in vitro and in vivo and have advanced to clinical trials. WIN 54954 significantly reduces the number and severity of colds induced by CVA21 and also significantly reduces nasal mucous discharge, respiratory and systemic symptoms, and viral titers. But, WIN 54954 was not further developed for clinical use because of adverse flushing and rash reactions, possibly related to concomitant alcohol ingestion by study volunteers.

Pleconaril (WIN 61893) is the first of a new generation of metabolically stable capsid function inhibitors. In a mouse model of multi-organ system infection following intracranial inoculation of HEVs, pleconaril reduced viral titers in all affected organs and prevented death in animals. The oral bioavailability in humans and other animals approaches 70%. Despite promising initial results, the drug was recently found to have no detectable clinical or virological benefit in infants with EV meningitis compared to that of a placebo.
Korean J Pediatr 2012;55(10):359-366 • http://dx.doi.org/10.3345/kjp.2012.55.10.359

2) SCH series
The SCH series developed by Schering-Plough inhibits plaque formation of several HEVs and protects mice infected with either CVB3 or ECV9 from mortality. These molecules act at an early stage in the viral replication cycle, and specifically interact with the viral capsid. However, the compounds do not prevent the attachment of the virus to the host cell, but rather exert their activity after the initial stage of viral uncoating.\(^\text{18,41}\)

3) Guanidine hydrochloride
Guanidine hydrochloride inhibits the replication of polioviruses, several CVs, and ECVs.\(^\text{18,42}\) Early studies using crude RNA replication complexes in vitro indicated that guanidine inhibited the initiation of viral RNA synthesis without inhibiting the elongation or release of completed positive-strand RNA molecules. A later study confirmed that the compound inhibits a 2C function that is required to initiate negative but not positive-strand RNA synthesis during RNA elongation.\(^\text{18,43}\)

4) Rupintrivir
Rupintrivir, developed by Pfizer, is a synthetic compound that is effective against all serotypes of human rhinovirus (HRV) and several HEV serotypes (CVB2 and 5, ECV6 and 9, and EV71) with low toxicity. This compound is highly specific for picornaviral protease and but is not active against cellular serine and cysteine proteases but has excellent irreversible inhibition capacity against protease.\(^\text{44}\) Rupintrivir has demonstrated moderate antiviral and clinical efficacy in Phase II clinical trials. But, further development was stopped because of a lack of efficacy in natural infection studies. The structures of the above listed compounds are shown in Table 5.\(^\text{18,44}\)

Table 5. Antiviral Agents Against Enteroviruses

| Compound     | Structure | Activity spectrum | Action mechanism                  |
|--------------|-----------|-------------------|-----------------------------------|
| WIN 54954    | ![Structure](image1.png) | Picornavirus       | Prevent of receptor binding and uncoating |
| Pleconaril   | ![Structure](image2.png) | Picornavirus       | Capsid function-inhibitor         |
| SCH 48973    | ![Structure](image3.png) | HEVs, HRVs         | Interact with the viral capsid    |
| Guanidine hydrochloride | ![Structure](image4.png) | PVs, HEVs, FMDV    | Inhibition of viral RNA synthesis |
| Rupintrivir  | ![Structure](image5.png) | HRV, CVBs, ECVs, EV71 | Inhibition of viral protease     |
| Ro 09-0179   | ![Structure](image6.png) | Picornavirus       | Suppression of viral replication  |
| 3-methoxyflavones | ![Structure](image7.png) | PV, CVs, HRV      | -                                |

Adapted from McSharry JJ, et al. Virology 1979;97:307-15\(^\text{30}\) and Binford SL, et al. Antimicrob Agents Chemother 2005;49:619-26\(^\text{44}\) HEV, human enterovirus; HRV, human rhinovirus; PV, poliovirus; FMDV, foot and mouth disease virus; CVB, coxsackievirus B; ECV, echovirus; EV, enterovirus.
2. Medicinal plant-based antiviral agents

An easy way to overcome the limitation of antiviral drugs is the screening of traditional medicinal plants. Medicinal plants, for their ability to have multiple targets, minor side effects, low potential to cause resistance, and low cost may be suitable alternative sources of antiviral agents. The screening of medicinal plants as a possible source of antiviral agents has led to the discovery of potent inhibitors of \textit{in vitro} viral growth and the use of the ethnopharmacological approach which enhances the probability of identifying new bioactive plant compounds\textsuperscript{45,46}. The structures of the below listed compounds are also shown in Table 5\textsuperscript{18}. Oseltamivir, was marketed under the trade name Tamiflu (Roche, Basel, Switzerland), is an IFN antiviral drug that originated from shikimic acid isolated from Chinese star anise, an ancient cooking spice; this herb is also used in traditional Chinese medicine.

1) Ro 09-0179

Ro 09-0179, which was isolated from a Chinese medicinal herb, exhibits \textit{in vitro} antiviral activity against a broad range of picornaviruses. This compound has been suggested to interfere with some viral replication processes that occur between viral uncoating and the initiation of viral RNA synthesis\textsuperscript{18,47}.

2) 3-Methoxyflavones

From a series of naturally occurring 3-methoxyflavones isolated from plant extracts of \textit{Euphorbia granitii}, 3-methylquercetin proved to be the most promising agent with \textit{in vitro} antiviral activity against poliovirus, CVs, and HRVs. This compound protects mice against a lethal CVB4 infection\textsuperscript{48}.

3) Chinese medicinal plants

Among Chinese medicinal plants, \textit{Sargentodoxa cuneata} (Oliv.) Rehd. Et Wils., \textit{Sophora tonkinensis} Gapnep., \textit{Paeonia veitchii} Lynch, \textit{Spatholobus suberectus} Dunn, and \textit{Cyrtomium fortunei} J. sm. have antiviral activity against CVB3 and 5 as well as ECV9 and 29 in an \textit{in vitro} test. However, it is unclear what these results signify for in vivo effectiveness. The results obtained in this preliminary screening justify continuing with the purification of crude extracts and isolating active compounds to assess their potential as antiviral drugs and/or finding new lead molecules\textsuperscript{49}. Although several hundreds of plants that have potential as novel antiviral agents have been studied, there still exists innumerable potentially useful medicinal plants waiting to be evaluated and exploited for therapeutic applications against genetically and functionally diverse virus families\textsuperscript{45,46}.

3. Strategy of searching for an antiviral agent

The development of a new antiviral drug is a difficult task considering the poorly selective toxicity and cost. To screen traditional medicinal plants is one way to overcome these problems. Another way to accelerate the availability of existing antiviral drugs is to approve them for an HEV antiviral effect. For example, amantadine, an M2 channel inhibitor for IFN and ribavirin that showed antiviral activity against ECV5 and 18 as well as EV71 in an \textit{in vitro} test (Fig. 2)\textsuperscript{31,32,50}.

Conclusions

This paper provides an overview of HEV infections, including the epidemiology of HEV infections in Korean children. HEVs cover a large genus of pathogens and can also be responsible for severe, potentially life-threatening diseases. However, until recently no HEV-specific antiviral drugs were available for clinical use. A great number of synthesized antiviral compounds directed against HEVs have been described but none have been approved for clinical use yet. Therefore, anti-enteroviral studies should be variously performed such as screening for traditional medicinal plants, the reposition of existing antiviral drugs as well as the development of new synthesized

![Fig. 2.](Reproduced from Park K, et al. Virol J 2011;8:79\textsuperscript{31} and Park K, et al. Virol J 2011;8:516\textsuperscript{50}).]
compounds in a search for antiviral agents against HEVs in the future. In addition to the acceleration of proper identification of antiviral treatments, systemic long-term epidemiological studies for HEV infections should be carried out.

Acknowledgment

This study was supported by the Soonchunhyang University Research Fund.

References

1. Thoelen I, Lemey P, Van Der Donck I, Beuselinck K, Lindberg AM, Van Ranst M. Molecular typing and epidemiology of enteroviruses identified from an outbreak of aseptic meningitis in Belgium during the summer of 2000. J Med Virol 2003;70:420-9.

2. Antona D, Leveque N, Chomel JJ, Dubrou S, Levy-Bruhl D, Lina B. Surveillance of enteroviruses in France, 2000-2004. Eur J Clin Microbiol Infect Dis 2007;26:403-12.

3. Cha SH. Recently prevalent infectious diseases among children: menigitis due to enteroviral infection. J Korean Med Assoc 2008;51:935-41.

4. Chang LY, Huang YC, Lin TY. Fulminant neurogenic pulmonary oedema with hand, foot, and mouth disease. Lancet 1998;352:367-8.

5. Ho M, Chen ER, Hsu KH, Twu SJ, Chen KT, Tsai SF, et al. An epidemic of enterovirus 71 infection in Taiwan. Taiwan Enterovirus Epidemic Working Group. N Engl J Med 1999;341:929-35.

6. Wang SM, Liu CC, Tseng HW, Wang JR, Huang CC, Chen YJ, et al. Clinical spectrum of enterovirus 71 infection in children in southern Taiwan, with an emphasis on neurological complications. Clin Infect Dis 1999;29:184-90.

7. Chang LY, Lee CY, Kao CL, Fang TY, Lu CY, Lee PL, et al. Hand, foot and mouth disease complicated with central nervous system involvement in Taiwan in 1980-1981. J Formos Med Assoc 2007;106:173-6.

8. Mizuta K, Abiko C, Murata T, Matsuzaki Y, Itagaki T, Sanjoh K, et al. Frequent importation of enterovirus 71 from surrounding countries into the local community of Yamagata, Japan, between 1998 and 2003. J Clin Microbiol 2005;43:6171-5.

9. Simonen-Tikka ML, Pflueger M, Klemola P, Savolainen-Kopra C, Smura T, Hummel S, et al. Human enterovirus infections in children at increased risk for type 1 diabetes: the Babydiet study. Diabetologia 2011;54:2995-3002.

10. Triantafyllopoulou A, Tapinos N, Moutsopoulos HM. Evidence for coxsackievirus infection in primary Sjögren’s syndrome. Arthritis Rheum 2004;50:2897-902.

11. Saitoh A, Sawyer MH, Leake JA. Acute disseminated encephalomyelitis associated with enteroviral infection. Pediatr Infect Dis J 2004;23:1174-5.

12. Chia J, Chia A, El-Habbal R. Carcinoid tumour associated with enterovirus infection. J Clin Pathol 2011;64:222-4.

13. Pouyt R, Kinnunen L, Hyypia T, Brown B, Horsnell C, Hovi T, et al. Genetic and phylogenetic clustering of enteroviruses. J Gen Virol 1996;77(Pt 8):1699-717.

14. Mayo MA, Pringle CR. Virus taxonomy: 1997. J Gen Virol 1998;79(Pt 4):649-57.

15. Modlin JF. Enteroviruses: coxsackieviruses, echoviruses, and newer enteroviruses. In: Long SS, Pickering LK, Prober CG, editors. Principles and practice of pediatric infectious disease. 3rd ed. Churchill Livingstone: Elsevier, 2008:1149-57.

16. National Center for Biotechnology Information. Taxonomy [Internet]. Bethesda: National Center for Biotechnology Information, U.S. National Library of Medicine; 2009 [cited 2012 Sep 25]. Available from: http://www.ncbi.nlm.nih.gov/taxonomy.

17. Abzug MJ. Nonpolioenteroviruses. In: Kliegman RM, Stanton BF, Geme JW, editors. Nelson textbook of pediatrics. 19th ed. Philadelphia: Saunders; 2011:1088-94.

18. De Palma AM, Vliegen I, De Clercq E, Neyts J. Selective inhibitors of picornavirus replication. Med Res Rev 2008;28:823-84.

19. Modlin JF. Coxsackieviruses, echoviruses, newer enteroviruses, and parechoviruses. In: Mandell GL, Bennett JE, Dolin R, editors. Mandell, Douglas, and Bennett’s principles and practice of infectious disease. 7th ed. New York: Elsevier, 2009:2353-65.

20. Sawyer MH. Enterovirus infections: diagnosis and treatment. Pediatr Infect Dis J 1999;18:1033-9.

21. Back K, Park K, Jung E, Chung E, Park J, Choi H, et al. Molecular and epidemiological characterization of enteroviruses isolated in Chungnam, Korea from 2005 to 2006. J Microbiol Biotechnol 2009;19:1055-64.

22. Kim HJ, Kang B, Hwang S, Hong J, Kim K, Cheon DS. Epidemics of viral meningitis caused by echovirus 6 and 30 in Korea in 2008. Virol J 2012;9:38.

23. Back K, Yeo S, Lee B, Park K, Song J, Yu J, et al. Epidemiics of enterovirus infection in Chungnam Korea, 2008 and 2009. Virol J 2011;8:297.

24. Eremenko T, Benedetto A, Volpe P. Virus infection as a function of the host cell life cycle: replication of poliovirus RNA. J Gen Virol 1972;16:61-8.

25. Lee BE, Davies HD. Aseptic meningitis. Curr Opin Infect Dis 2007;20:272-7.

26. Ryu WS, Kang B, Hong J, Hwang S, Kim A, Kim J, et al. Enterovirus 71 infection with central nervous system involvement, South Korea. Emerg Infect Dis 2010;16:1764-6.

27. Centers for Disease Control and Prevention (CDC). Nonpolio enterovirus and human parechovirus surveillance: United States, 2006-2008. MMWR Morb Mortal Wkly Rep 2010;59:1577-80.

28. Jacques J, Moret H, Minette D, Leveque N, Jovenin N, Deslee G, et al. Epidemiological, molecular, and clinical features of enterovirus respiratory infections in French children between 1999 and 2005. J Clin Microbiol 2008;46:206-13.

29. Jee Y, Cheon D, Choi W, Ahn J, Kim K, Chung Y, et al. Updates on enterovirus surveillance in Korea. Infect Chemother 2010;46:289-303.

30. Sawant VS, Lee B, Park K, Park J, Park J, Choi H, et al. Molecular and epidemiological characterization of enteroviruses isolated in Chungnam, Korea from 2005 to 2006. J Microbiol Biotechnol 2009;19:1055-64.

31. Park K, Song J, Lee C, Kim D, Cho S, et al. Genetic diversity of a Korean echovirus 5 isolate and response of the strain to five antiviral drugs. Virol J 2011;8:79.

32. Park K, Yeo S, Baek K, Cheon D, Choi Y, Park J, et al. Molecular characterization and antiviral activity test of common drugs against echovirus 18 isolated in Korea. Virol J 2011;8:516.

33. Rotbart HA. Treatment of picornavirus infections. Antiviral Res
34. Carrasco L. Picornavirus inhibitors. Pharmacol Ther 1994;64:215-90.
35. De Clercq E. Antiviral drugs in current clinical use. J Clin Virol 2004;30:115-33.
36. McSharry JJ, Caliguiri LA, Eggers HJ. Inhibition of uncoating of poliovirus by arildone, a new antiviral drug. Virology 1979;97:307-15.
37. Caliguiri LA, McSharry JJ, Lawrence GW. Effect of arildone on modifications of poliovirus in vitro. Virology 1980;105:86-93.
38. Turner RB, Dutko FJ, Goldstein NH, Lockwood G, Hayden FG. Efficacy of oral WIN 54954 for prophylaxis of experimental rhinovirus infection. Antimicrob Agents Chemother 1993;37:297-300.
39. Pevear DC, Tull TM, Seipel ME, Groarke JM. Activity of pleconaril against enteroviruses. Antimicrob Agents Chemother 1999;43:2109-15.
40. Abzug MJ, Cloud G, Bradley J, Sanchez PJ, Romero J, Powell D, et al. Double blind placebo-controlled trial of pleconaril in infants with enterovirus meningitis. Pediatr Infect Dis J 2002;21:335-41.
41. Rozhon E, Cox S, Buontempo P, O'Connell J, Slater W, De Martino J, et al. SCH 38057: a picornavirus capsid-binding molecule with antiviral activity after the initial stage of viral uncoating. Antiviral Res 1993;21:15-35.
42. Caliguiri LA, Tamm I. Action of guanidine on the replication of poliovirus RNA. Virology 1968;35:408-17.
43. Barton DJ, Flanagan J. Synchronous replication of poliovirus RNA: initiation of negative-strand RNA synthesis requires the guanidine-inhibited activity of protein 2C. J Virol 1997;71:8482-9.
44. Binford SL, Maldonado F, Brothers MA, Wady PT, Zalman LS, Meador JW 3rd, et al. Conservation of amino acids in human rhinovirus 3C protease correlates with broad-spectrum antiviral activity of rupintrivir, a novel human rhinovirus 3C protease inhibitor. Antimicrob Agents Chemother 2005;49:619-26.
45. Briskin DP, Medicinal plants and phytomedicines. Linking plant biochemistry and physiology to human health. Plant Physiol 2000;124:507-14.
46. Jassim SA, Naji MA. Novel antiviral agents: a medicinal plant perspective. J Appl Microbiol 2003;95:412-27.
47. Cushnie TP, Lamb AJ. Antimicrobial activity of flavonoids. Int J Antimicrob Agents 2005;26:343-56.
48. Van Hoof L, Vanden Berghe DA, Hatfield GM, Vlietinck AJ. Plant antiviral agents: V. 3-Methoxyflavones as potent inhibitors of viral-induced block of cell synthesis. Planta Med 1984;50:513-7.
49. Guo JP, Pang J, Wang XW, Shen ZQ, Jin M, Li JW. In vitro screening of traditionally used medicinal plants in China against enteroviruses. World J Gastroenterol 2006;12:4078-81.
50. Chen YJ, Zeng SJ, Hsu JT, Horng JT, Yang HM, Shih SR, et al. Aminopterin as a regulator of internal ribosome entry site. Acta Pharmacol Sin 2008;29:1327-33.